Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 195
Report ID: PMRREP33939
The global Primary Care POC Diagnostics market is forecast to expand at a CAGR of 6.4% and thereby increase from US$ 16.3 Bn in 2024 to US$ 25.2 Bn by the end of 2031.
|
Attributes |
Key Insights |
|
Market Size (2024E) |
US$ 16.3 Bn |
|
Projected Market Value (2031F) |
US$ 25.2 Bn |
|
Global Market Growth Rate (CAGR 2024 to 2031) |
6.4% |
|
Historical Market Growth Rate (CAGR 2019 to 2023) |
4.9% |
|
Revenue Share of Top Four Countries (2023E) |
45% |
Principal care Point-of-care diagnostics, commonly used in primary healthcare contexts such as clinics or doctor's offices, denotes medical procedures performed near the patient. These tests enable the provision of prompt and accurate results. These diagnostic tools empower medical professionals to promptly determine patient care, thereby promoting timely interventions and individualized treatment strategies. These tests encompass a diverse array of medical parameters, such as cholesterol levels, blood glucose levels, and infectious diseases, among others. Their utilization promotes the administration of healthcare that is both efficient and patient-centered.
The increasing prevalence of chronic diseases, rising demand for rapid and accurate diagnostic instruments in primary care settings, and technological advancements that improve the capabilities of point-of-care testing devices are all factors that propel the global primary care POC diagnostics market. Moreover, the increasing focus on early disease detection and preventive healthcare, in conjunction with the demand for accessible and economical diagnostic solutions, drives the market forward. The growth of the market is significantly influenced by the integration of connectivity and data management systems, as well as the expansion of healthcare infrastructure in emerging markets.
Escalating Incidence of Chronic Illnesses
One of the primary care POC diagnostics market factors propelling the worldwide point-of-care diagnostics market is the escalating incidence of chronic illnesses. An increasing number of chronic ailments, including cardiovascular diseases, infectious diseases, and diabetes, have compelled a paradigm shift in healthcare toward proactive and individualized patient management. The increased prevalence of chronic diseases on a global scale has led to a heightened need for primary care diagnostic solutions that are both efficient and timely. Point-of-care diagnostics address this requirement through the provision of immediate and continuous testing, which empowers medical practitioners to formulate prompt judgments concerning the interventions and treatment strategies of patients.
A variety of factors contribute to the increase in chronic diseases, including dietary adjustments, aging populations, and lifestyle changes. A lack of physical activity, sedentary lifestyles, and hazardous diets all contribute to the rising prevalence of conditions such as cardiovascular disease and diabetes. Furthermore, the aging population is a substantial factor to consider, as elderly people are more prone to developing chronic health conditions. Furthermore, on a global scale, infectious diseases such as hepatitis and HIV remain formidable obstacles. The high incidence of these illnesses underscores the need for readily available diagnostic instruments in primary care settings to aid in the timely identification and control of the conditions. Chronic diseases have repercussions that transcend the well-being of individuals, placing stress on healthcare systems and resources. By providing a time-efficient and cost-effective method of diagnosis, point-of-care diagnostics alleviate the strain on healthcare facilities.
Assurance of Precision and Dependability of these Rapid Testing Technologies
The global market for point-of-care diagnostics is impeded by regulatory obstacles related to the assurance of precision and dependability of these rapid testing technologies. The increasing demand for point-of-care diagnostics is accompanied by rigorous standards set by regulatory bodies across the globe to ensure the accuracy and excellence of these examinations. Ensuring adherence to regulatory standards, including those established by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), can impose significant financial and time burdens on manufacturers. To establish the effectiveness and safety of these tests, comprehensive validation, and clinical evidence are required by the regulatory framework governing diagnostic devices. The pursuit of adherence to regulatory standards may necessitate the postponement of product development and market entry schedules.
Ongoing Concern Regarding Reimbursement Uncertainties
One of the most significant obstacles for the worldwide primary care point-of-care diagnostics market is the ongoing concern regarding reimbursement uncertainties. The reimbursement environment for point-of-care testing continues to be intricate, with variations observed among distinct healthcare systems and regions. There are situations where reimbursement policies fail to sufficiently correspond with the decentralized and expeditious characteristics of point-of-care diagnostics. This can result in financial difficulties for diagnostic manufacturers and healthcare providers. The necessity for transparent policies that acknowledge the value of rapid diagnostics in enhancing primary care efficiency, lowering overall healthcare expenditures, and improving patient outcomes gives rise to reimbursement challenges.
Swift Progression of Technology
One of the key factors propelling the worldwide point-of-care diagnostics market is the swift progression of technology, specifically in the domains of data analytics, connectivity, and miniaturization. The perpetual advancement of technology has substantially augmented the functionalities of point-of-care diagnostic devices, resulting in increased sophistication, precision, and usability. Miniaturization facilitates the creation of portable and transportable diagnostic devices, which empower medical professionals to perform an extensive array of examinations using negligible sample volumes, frequently near the patient's bedside. By doing so, the diagnostic process is not only optimized but also the turnaround time for results is diminished, which facilitates prompter decisions regarding patient care.
The opportunistic environment is significantly influenced by connectivity, which facilitates the smooth transmission of data and the integration of electronic health records (EHRs). The integration of diagnostic devices enables the exchange of data in real time between point-of-care instruments and healthcare information systems, thereby enhancing the efficiency of information transmission within healthcare networks. The provision of connectivity not only facilitates the retrieval of patient information but also provides support for telemedicine and remote monitoring endeavors. With the growing adoption of digital transformation in the healthcare sector, the incorporation of electronic health records and point-of-care diagnostics becomes critical for establishing a cohesive and all-encompassing healthcare ecosystem.
What Product Will Be Targeted the Most for Installations?
Glucose Testing Sector to be Dominant owing to Increasing Incidences of Diabetes
According to projections, the glucose testing sector will hold the most significant portion of the primary care point-of-care diagnostics market. Due to the rising incidence of diabetes and the imperative for consistent surveillance, glucose testing assumes a pivotal function within primary care environments, solidifying its status as a prevailing and indispensable sector. The infectious diseases segment of the primary care point-of-care diagnostics market is anticipated to expand at the highest rate. The increased worldwide consciousness regarding contagious illnesses, particularly given recent pandemics, propels the need for prompt and immediate diagnostic procedures. Effective disease management necessitates the ability to promptly diagnose infectious diseases in primary care settings; therefore, this sector is positioned for substantial expansion in the future years.
Which End User to Be Focused on the Most Regarding Sales?
Physician Offices to Utilize Technology Rapidly owing to their Prompt Assessment
Predictably, the physician office segment will hold the most market share of the market for point-of-care diagnostics for primary care. Physician offices are critical centers for primary healthcare; the incorporation of point-of-care (POC) diagnostics in these environments enables prompt assessment and well-informed judgment throughout patient consultations, thereby bolstering the prominence of this sector. It is anticipated that urgent care clinics will experience the most rapid growth in the primary care point-of-care diagnostics market. Urgent care clinics are of paramount importance in the provision of expedient healthcare services; therefore, the implementation of point-of-care (POC) diagnostics in these environments not only improves efficiency but also patient care through the expeditious delivery of results for a wide range of medical tests. Point-of-care testing's rapid turnaround and convenience are highly compatible with the urgent care model, which has contributed to the segment's explosive growth.
Region's Early Adoption of Sophisticated Medical Technologies to Promote Growth
It is anticipated that North America will hold the largest market share of the worldwide primary care point-of-care diagnostics market. The region's early adoption of sophisticated medical technologies, a robust healthcare infrastructure, and high healthcare expenditures all contribute to this dominance. The increasing prevalence of chronic diseases and the growing focus on preventive healthcare contribute to the need for streamlined and expeditious diagnostic systems in primary care environments. Additionally, the pervasive adoption of point-of-care diagnostics in healthcare facilities across North America is facilitated by favorable reimbursement environments and regulatory frameworks. North America's leadership in the primary care point-of-care diagnostics market is bolstered by the presence of significant market participants, continuous technological advancements, and a proactive healthcare approach. Point-of-care testing adoption is additionally bolstered by the region's dedication to enhancing patient outcomes and diminishing healthcare expenditures. Furthermore, the escalation of communicable illnesses, as exemplified by recent worldwide health emergencies, emphasizes the criticality of prompt and precise diagnoses, thereby augmenting the need for proof-of-concept testing solutions in North America.
Large and Diverse Population and Rising Healthcare Awareness to Generate Revenue
It is anticipated that South Asia and the Pacific will witness the most rapid expansion of the worldwide primary care point-of-care diagnostics market. A large and diverse population, rising healthcare awareness, and an increase in the prevalence of chronic diseases all contribute to this expansion. The rapid integration of point-of-care (POC) diagnostics in primary care contexts can be attributed to the region's expanding healthcare infrastructure and the use of technology in healthcare delivery. A growing focus exists in South Asia and the Pacific region on improving healthcare accessibility in remote and underserved areas; in this regard, point-of-care testing has the potential to bring about significant changes. The pursuit of prompt and economical diagnostic solutions is to the healthcare objectives of the area. Increasing healthcare expenditures, technological advancements in diagnostics, and government initiatives that provide support all contribute to the expansion of the primary care point-of-care diagnostics market in South Asia & Pacific. It is anticipated that the implementation of point-of-care testing will increase significantly as healthcare systems in this region progress, thereby tackling healthcare obstacles and enhancing patient results.
The global market for primary care point-of-care (POC) diagnostics is anticipated to experience strong expansion, propelled by a convergence of elements that collectively emphasize its importance in contemporary healthcare. An important determinant is the increasing incidence of chronic diseases on a global scale. The increasing prevalence of ailments such as cardiovascular disorders, infectious diseases, and diabetes necessitates primary care diagnostic solutions that are both effective and expeditious. Point-of-care (POC) diagnostics, by their ability to deliver test results instantly, empower healthcare practitioners to render prompt judgments, thereby fostering enhanced patient outcomes and the efficient provision of healthcare at a reasonable cost. Technological advancements, specifically in the domains of miniaturization, connectivity, and data analytics, offer a substantial prospect for expansion. The ongoing progression of point-of-care diagnostic devices results in improvements to their precision, velocity, and usability. The integration of electronic health records (EHRs) enables the sharing of data in real time, whereas miniaturization enables the development of transportable and portable devices.
Connectivity, meanwhile, promotes a more streamlined and integrated healthcare system. In addition, by integrating data analytics, more informed clinical decisions can be made regarding treatment outcomes, disease trends, and population health. This facilitates the acquisition of valuable insights. As the market places a greater emphasis on preventive healthcare and early disease detection, the future appears bright. Proof-of-concept diagnostics are in complete accordance with these goals as they provide expeditious and easily obtainable testing remedies. The increasing emphasis on proactive and individualized patient management within healthcare systems worldwide is anticipated to drive demand for point-of-care diagnostics. Furthermore, the integration of proof-of-concept (POC) testing into primary care systems and the broadening of its utility beyond conventional laboratory environments exert an impact on the trajectory of the market.
Supply-side Dynamics
The global primary care Point-of-Care (POC) diagnostics market is dominated by BD (Becton, Dickinson, and Company), Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. Prominent in the market, these organizations provide an extensive selection of proof-of-concept diagnostic solutions. The United States is a market leader in terms of adoption, primarily due to its well-developed healthcare infrastructure and the significant prevalence of chronic diseases in the country. European nations such as Germany and the United Kingdom demonstrate significant levels of adoption as well. Prominent Asian economies, China and India in particular, are swiftly adopting point-of-care (POC) diagnostics as a means to tackle healthcare obstacles in densely populated areas. As an illustration, India employs point-of-care (POC) testing to facilitate prompt HIV diagnosis in geographically isolated regions, thereby assuring prompt interventions and alleviating the strain on healthcare infrastructure.
Prominent entities in the primary care point-of-care diagnostics industry are exerting influence and revolutionizing the sector via strategic alliances, acquisitions, and technological progress. Pharmaceutical corporations such as Roche and Abbott are making substantial R&D investments to improve the capabilities and performance of their point-of-care diagnostic devices. In addition to diversifying their healthcare requirements, these companies are expanding their product lines to encompass a wider array of medical parameters. Partnerships established with healthcare institutions and regulatory bodies facilitate the smooth incorporation of point-of-care diagnostics into standard clinical procedures. Furthermore, the increasing focus on connectivity and data analytics is revolutionizing point-of-care diagnostics into sophisticated, data-centric instruments that enable healthcare practitioners to make more informed judgments. The dedication of market leaders to the progression of proof-of-concept (POC) technologies is crucial for driving market growth and guaranteeing the extensive implementation of these groundbreaking diagnostic solutions.
Prominent entities in the worldwide primary care Point-of-Care (POC) diagnostics industry, such as BD (Becton, Dickinson, and Company), Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, utilize strategic initiatives to safeguard and optimize their market presence. Consistent investment in research and development (R&D) to foster innovation and improve their point-of-care (POC) diagnostic offerings constitutes a noteworthy strategy. These corporations devote significant resources to the development of state-of-the-art technologies that enhance the precision, velocity, and scope of diagnostic examinations. As an illustration, Roche Diagnostics is renowned for its pioneering efforts in the field of molecular diagnostics, whereas Abbott Laboratories is committed to the development of comprehensive diagnostic platforms that cater to diverse healthcare environments. Siemens Healthineers invests in digital solutions, and BD's contributions to medical technology are notable.
Furthermore, the industry leaders prioritize regulatory adherence and the acquisition of essential certifications to guarantee that their products satisfy worldwide criteria for effectiveness and safety. Ensuring adherence to regulatory obligations is of the utmost importance to obtain endorsement from health authorities and healthcare practitioners, thereby fostering trust in the dependability of their point-of-care diagnostic devices. Additionally, market leaders employ strategic acquisitions as a means to expand their range of products and fortify their competitive standing. By acquiring complementary businesses, these organizations can provide all-encompassing solutions that span a broad range of medical parameters. Abbott Laboratories, for instance, strengthened its position in the POC diagnostics market through the expansion of its capabilities in infectious disease and cardiometabolic testing through the acquisition of Alere.
New Partnership
Digital Diagnostics and Baxter International Inc. formed a long-term strategic partnership in March 2022 to enable the point-of-care detection of diabetic retinopathy using the Welch Allyn RetinaVue 700 Imager in conjunction with IDx-DR autonomous AI software.
Market Impact:
The collaboration between Baxter International Inc. and Digital Diagnostics, with a specific emphasis on the utilization of the Welch Allyn RetinaVue 700 Imager and IDx-DR autonomous AI software for point-of-care detection of diabetic retinopathy, signifies a noteworthy progression in the field of digital diagnostics about complications associated with diabetes. By enhancing the accessibility and efficacy of diabetic retinopathy screening at the point of care, this collaboration has the potential to improve the management of this vision-threatening complication on a global scale through early detection, timely intervention, and enhanced accessibility. The amalgamation of sophisticated imaging technology and self-governing artificial intelligence software highlights a paradigm shift in the provision of healthcare, specifically concerning the management of diabetes.
|
Attribute |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2019 to 2023 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
Roche Diagnostics
BD Biosciences
Danaher Corporation
Abbott Laboratories
Instrumentation Laboratory
bioMerieux
Siemens Healthcare
Quidel Corporation
The market is anticipated to grow at a CAGR of 6.4% during the projected period.
The Primary Care POC Diagnostics market was valued at USD 16,385.8 million in 2023.
The United States held the largest market share in 2023.
The prominent players in the market are Roche Diagnostics, BD Biosciences, Danaher Corporation, and Abbott Laboratories, among others.
The pharmacy & retail clinics segment is expected to grow at the fastest growth during the forecast period.
